Syntheses and structure-activity relationships of taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III

被引:124
作者
Ojima, I [1 ]
Slater, JC [1 ]
Kuduk, SD [1 ]
Takeuchi, CS [1 ]
Gimi, RH [1 ]
Sun, CM [1 ]
Park, YH [1 ]
Pera, P [1 ]
Veith, JM [1 ]
Bernacki, RJ [1 ]
机构
[1] ROSWELL PK CANC INST,GRACE CANC DRUG CTR,DEPT EXPT THERAPEUT,BUFFALO,NY 14263
关键词
D O I
10.1021/jm960563e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of new taxoids derived from 14 beta-hydroxy-10-deacetylbaccatin III was synthesized by means of the beta-lactam synthon method. Most of the new taxoids thus synthesized possess excellent cytotoxicity against human ovarian (A121), non-small-cell lung (A549), colon (HT-29), and breast (MCF-7) cancer cell Lines, and several of these taxoids show subnanomolar IC50 values which are severalfold to 1 order of magnitude better than those of paclitaxel and docetaxel. Modifications at the 3'- and 3'-N-positions exert marked effects on the activity. For the substituents at C-3', the cytotoxicity decreases in the order 2-furyl similar to 2-methyl-1-propenyl greater than or equal to 2-methylpropyl > (E)-1-propenyl greater than or equal to n-propyl > phenyl much greater than 2,2-dimethylpropyl. For the 3'-N substituents, the activity decreases in the order t-BuOCO > Ph > n-hexanoyl. A significant increase in the cytotoxicity against the doxorubicin-resistant human breast cancer cell line MCF7-R that expresses the multidrug resistance (MDR) phenotype is observed by the proper modification of the substituent at C-10. The observed remarkable effects of the substituents at C-10 on the activity against MCF7-R can be ascribed to the effective inhibition of the binding of these new taxoids to P-glycoprotein that is responsible for MDR.
引用
收藏
页码:267 / 278
页数:12
相关论文
共 36 条
  • [1] 14-BETA-HYDROXY-10-DEACETYLBACCATIN-III, A NEW TAXANE FROM HIMALAYAN YEW (TAXUS-WALLICHIANA ZUCC)
    APPENDINO, G
    GARIBOLDI, P
    GABETTA, B
    PACE, R
    BOMBARDELLI, E
    VITERBO, D
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1992, (21): : 2925 - 2929
  • [2] ARBUCK SG, 1995, TAXOL SCI APPL, P379
  • [3] Georg G I., 1995, Taxane Anticancer Agents: Basic Science and Current Status
  • [4] SYNTHESIS OF BIOLOGICALLY-ACTIVE TAXOL ANALOGS WITH MODIFIED PHENYLISOSERINE SIDE-CHAINS
    GEORG, GI
    CHERUVALLATH, ZS
    HIMES, RH
    MEJILLANO, MR
    BURKE, CT
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (22) : 4230 - 4237
  • [5] HETEROAROMATIC TAXOL ANALOGS - THE CHEMISTRY AND BIOLOGICAL-ACTIVITIES OF 3'-FURYL AND 3'-PYRIDYL SUBSTITUTED TAXANES
    GEORG, GI
    HARRIMAN, GCB
    HEPPERLE, M
    HIMES, RH
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (11) : 1381 - 1384
  • [6] AN EFFICIENT SEMISYNTHESIS OF TAXOL FROM (3R,4S)-N-BENZOYL-3-[(T-BUTYLDIMETHYLSILYL)OXY]-4-PHENYL-2-AZETIDINONE AND 7-(TRIETHYLSILYL)BACCATIN III
    GEORG, GI
    CHERUVALLATH, ZS
    HARRIMAN, GCB
    HEPPERLE, M
    PARK, H
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (11) : 2467 - 2470
  • [7] TAXOL AND TAXOTERE - DISCOVERY, CHEMISTRY, AND STRUCTURE-ACTIVITY-RELATIONSHIPS
    GUENARD, D
    GUERITTEVOEGELEIN, F
    POTIER, P
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 1993, 26 (04) : 160 - 167
  • [8] STRUCTURE OF A SYNTHETIC TAXOL PRECURSOR - N-TERT-BUTOXYCARBONYL-10-DEACETYL-N-DEBENZOYLTAXOL
    GUERITTEVOEGELEIN, F
    GUENARD, D
    MANGATAL, L
    POTIER, P
    GUILHEM, J
    CESARIO, M
    PASCARD, C
    [J]. ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1990, 46 : 781 - 784
  • [9] Holton R. A., 1992, US Patent, Patent No. [5,175,315, 5175315]
  • [10] Holton R. A., 1990, Patent No. [EP 0400971 A2, 0400971]